The expression of the c-erbB-2 oncogene has been evaluated using an immunohistochemical technique with the 21N polyclonal antibody in paraffin embedded tissue from 465 patients treated between the years [1975][1976][1977][1978][1979][1980][1981] for Stage I and II breast cancer. One hundred and four (22%) patients exhibited positive staining. This was not associated with any other variables. Expression of the oncogene was associated with significantly poorer survival which was independent of other tumour variables.
The proto-oncogene c-erbB-2 encodes a protein present at the cell surface which has considerable homology with the epidermal growth factor receptor EGFR (Coussens et al., 1985) . Although originally identified as an oncogene in chemically induced neuroblastomas in rats (Pahdy et al., 1982; Bargmann et al., 1986) , recent interest has focused on its role in human breast cancer. Studies on cell lines derived from human mammary carcinomas have demonstrated that c-erbB -2 can be overexpressed by several mechanisms including gene amplification (Kraus et al., 1987) and this is present in up to 30% of human breast cancers (Slamon et al., 1987; de Vijver et al., 1987; Varley et al., 1987; Zhou et al., 1987) .
The development of both polyclonal and monoclonal antibodies to the oncoprotein has allowed its distribution to be evaluated in histological sections, and its presence and clinical significance to be correlated with amplification of its gene and expression of its mRNA (Venter et al., 1987; de Vijver et al., 1987; Slamon et al., 1989; Gusterson et al., 1988) . These studies have confirmed that both gene amplification and increased transcription of its mRNA are associated with expression of this putative receptor at the cell surface in patients with breast cancer. One study though has reported that 20% of patients expressing this receptor failed to exhibit a corresponding amplification of its gene (Berger et al., 1988) and has concluded that other mechanisms may also be of importance in allowing it to be expressed.
In both molecular studies and those based on immunological detection of the protein expression of the receptor has been associated with the spread of tumour to the axillary lymph nodes, to the number of nodes involved (Zhou et al., 1987; Slamon et al., 1987 Slamon et al., , 1989 , larger tumours (van de Vijver et al., 1987) and with poor histological grade (Berger et al., 1988) . However, the number of patients assessed in these studies is variable and some have contained too few patients to evaluate the statistical significance of the data. Reports of its clinical significance have been conflicting, with some investigators noting a poorer prognosis in patients expressing the protein (Slamon et al., 1989; Wright et al., 1989a; Lovekin et al., 1989) and others reporting little difference (Barnes et al., 1988; Zhou et al., 1989; Alli et al., 1988; Gusterson et al., 1988 UK) was carried out at a dilution of 1:50 for 30 min. After further washing of the sections there was a final incubation with a complex of horse radish peroxidase and rabbit anti-horse radish peroxidase (PAP complex) (Dako Labs., Bucks, UK) at a dilution of 1:100 for 30 min. All antibody incubations were performed at room temperature in a humidified chamber. Sections were again washed and the reaction product that followed addition of hydrogen peroxide was visualised by incubation with 0.02% 3-amino-9-ethylcarbazole in 0.1 M acetate buffer (pH 5.2) for 20 min. This gives a red brown precipitate. Sections were finally washed and counterstained with Mayers Haemalun before mouting in hydromount (Mensura Technology Ltd, Lancs, UK). In addition, negative control slides were prepared using a blocking peptide to exclude any non-specific binding.
Evaluation
Slides were evaluated by light microscopy; if at least one focus of positively stained malignant cells was observed the section was considered positive. Staining intensity was evaluated on a scale from 1 to 4 based on the proportion of malignant cells in the section stained, grade 1 = up to 25%, grade 2 = 25-50%, grade 3 = 50-75% and grade 4 = 75-100%. Slides were initially read by one observer (J.W.) and interobserver variation was determined after further assessment by two independent pathologists. Two sections were cut and stained separately from each slide and in doubtful or borderline cases further sections were cut and stained in the same way. There was full agreement in 95% of slides in both assessment of staining and its grade, and an intratumour variation rate of 6%.
Statistical methods
Survival analyses were performed to relate survival time to c-erbB-2 staining (positive or negative), lymph node status (positive or negative), oestrogen receptor status (positive or negative) and tumour size (TI, T2 or T3). The close of the study was taken as 1st January 1990, and patients known to be alive at this date, or who had died earlier from causes unrelated to cancer, were treated as censored observations.
Univariate analyses were performed using Kaplan-Meier estimates and log-rank tests. Multivariate analysis was performed with the Cox proportional hazards regression model, using both forward and backward stepwise selection of variables. Tests for interactions were performed within the model containing the main effects of all four prognostic variables.
Results
Histological sections of 465 tumours were incubated with anti c-erbB-2; 361 (78%) failed to demonstrate any staining whilst the remaining 104 (22%) stained positively. Staining was confined primarily to the cell membrane of malignant cells although, occasionally, some intracellular cytoplasmic staining was seen. In one instance some faint staining was seen in a focus of benign fibrocystic disease, but this was surrounded by elements of intraductal carcinoma. No positive staining was seen in any of the benign breast biopsies stained. Incubation of adjacent serial sections of the positively staining tumours with anti serum pre-incubated with c-erbB-2 related peptide inhibited completely any staining.
The presence of c-erbB-2 was cross-tabulated with other tumour variables (Table I) . These included tumour size, nodal status, and oestrogen receptor status. Although there was a trend for the presence of c-erbB-2 staining to be associated with larger tumours this failed to achieve statistical significance (P = 0.054). No other associations of significance were noted.
Univariate analysis of overall survival c-erbB-2 The overall survival of the 104 patients whose tumours expressed the c-erbB-2 protein was significantly worse than in those whose tumours failed to express it (Log rank x2 = 4.90, 1 d.f., P = 0.03). The improved survival of patients with negatively stained tumours was maintained throughout the period of follow up (Figure 1 Figure 1 Relationship of c-erbB-2 to overall survival. associated with poor prognosis although this was only statistically significant for node negative patients (log rank x2 = 4.45, P<0.03) (Figure 2 ).
Oestrogen receptor status There was no consistent association between oestrogen receptor status and survival (log rank x2 = 2.90, 1 d.f., P = 0.09). Stratifying the patients further by c-erbB-2 status also gave no suggestion of a consistent association between oestrogen receptor status and survival, although there was a non-significant trend towards a poorer prognosis was seen in oestrogen receptor positive patients expressing the c-erbB-2 protein (Figure 3 ).
Tumour size
Tumour size was also found to be a powerful prognostic factor (log rank x2 = 19.10, 2 d.f., P = 0.0001).
Multivariate analysis of overall survival Nodal status and tumour size were clearly powerful independent prognostic factors, and, controlling for these, c-erbB-2 was also significantly related to survival. Figure 3 Relationship of c-erbB-2 to survi tor sub-groups. (Slamon et al., 1987 (Slamon et al., , 1989 . It ha archival paraffin-embedded material expression because antigens may be (Slamon et al., 1989) . In order to eva separate study (results not reported) i freshly collected tissue fixed in methac; after fixation in exactly the same way .
brbB-2(+)/node(-) A similar level of expression was seen in this group to that in ,rbB-2( -)/node(-) the archival group. Moreover, the same results were obtained rbB-2(-)/node(+) with an entirely separate monoclonal antibody to c-erbB-2. Similarly, although multiple serial sections were not stained (Slamon et Overall survival for patients with tumours expressing the c-erbB-2 receptor was significantly worse than in those with tumours not expressing it. This poor prognostic effect was observed throughout the period of follow-up, and these findings are similar to those observed in other studies (Slamon et 8 10 12 al., 1989; Wright et al., 1989a; Lovekin et al., 1989 Il ------------1... n phenotype in breast cancer. This ligand may be a novel growth factor which, after binding, modifies the response of cells expressing the receptor to such factors as tumour necrosis factor (Hudziack et al., 1989) or part of a cell-cell signalling apparatus (Gusterson et al., 1988; Quirke et al., 1989 ).
Our results indicate that the proto-oncogene c-erbB-2 is associated with a poor prognosis in breast cancer. It remains to be determined what clinical significance it has in early and in situ breast cancers and what role it plays in the development of the disease.
